Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Dietary Protein and Monocyte/Macrophage Mammalian Target of Rapamycin (mTOR) Signaling

NCT03946774
View directory record Official record
Conditions
Dietary Protein
Interventions
Dietary protein shake
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 30, 2026, 2:34 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS

NCT02048969
View directory record Official record
Conditions
Hepatic Encephalopathy, Liver Cirrhosis
Interventions
Flumazenil, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 30, 2026, 2:34 PM EDT
Recruiting Phase 3 Interventional

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 2:34 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults

NCT07831473
View directory record Official record
Conditions
Randomised Clinical Trial, Double Blind, Dengue, Challenge Test, Dose Escalation and Safety
Interventions
VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant, ALFQ adjuvant + Saline, rDEN3Delta30
Biological
Lead sponsor
VLP Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 2:34 PM EDT
Completed Phase 4 Interventional

Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes

NCT00110370
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lispro Mixture Therapy, Glargine Basal-Bolus Therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced Oct 30, 2026, 2:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder

NCT02478788
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
mixed amphetamine salts-extended release (MAS-XR), Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 30, 2026, 2:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Food Additives Effects on EEG Profiles in College Students With ADHD

NCT03342469
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Artificial Food Coloring, Placebo
Other
Lead sponsor
American University
Other
Eligibility
18 Years to 24 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 30, 2026, 2:34 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

NCT05146739
View directory record Official record
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Cytarabine, Fludarabine, Leucovorin, Triple Intrathecal Chemotherapy, Uproleselan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 30, 2026, 2:34 PM EDT
Active, not recruiting Phase 2 Interventional

A Study in Patients With Mixed Dyslipidemia

NCT06497127
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
BW-00112
Drug
Lead sponsor
Shanghai Argo Biopharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Daphne, Alabama • Mobile, Alabama • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 30, 2026, 2:34 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

NCT05566041
View directory record Official record
Conditions
Carcinoma, Small Cell Lung
Interventions
RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Tampa, Florida • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 30, 2026, 2:34 PM EDT
Completed Phase 1Phase 2 Interventional

Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants

NCT00228319
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Oral Ascorbic Acid, Paclitaxel, Carboplatin, Sodium Ascorbate, Oral Mixed natural Carotenoids with Vitamin A, Vitamin E
Dietary Supplement · Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 30, 2026, 2:34 PM EDT
Withdrawn No phase listed Observational

Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant

NCT00898612
View directory record Official record
Conditions
Lymphoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 30, 2026, 2:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Two Teaching Techniques to Teach Cardiac Auscultation to Physicians

NCT01596465
View directory record Official record
Conditions
Heart Murmur
Interventions
Self-Study using MP3 Player, Multimedia Lecture
Other
Lead sponsor
The Reading Hospital and Medical Center
Other
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 30, 2026, 2:34 PM EDT
Completed Not applicable Interventional Results available

Vagal Nerve Stimulation and Glucose Metabolism

NCT01117311
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Gastric Emptying
Interventions
VNB on, VNB off
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 30, 2026, 2:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparing Reduction With ESD- Versus APC-TORe

NCT06131281
View directory record Official record
Conditions
Obesity, Roux-en-y Anastomosis Site, Weight Gain
Interventions
E-TORe, c-TORe
Procedure
Lead sponsor
Stephen Firkins
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 2:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients

NCT00113919
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Busulfan
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 30, 2026, 2:34 PM EDT
Completed Phase 2 Interventional Results available

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01666444
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
136
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 30, 2026, 2:34 PM EDT
Terminated Not applicable Interventional Results available

SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation

NCT01434745
View directory record Official record
Conditions
Smith-Lemli-Opitz Syndrome
Interventions
Simvastatin, Lactose
Drug · Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Year to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 30, 2026, 2:34 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

A Study of Communication Between Clinicians, Patients, and Families in the Intensive Care Unit (ICU)

NCT06042621
View directory record Official record
Conditions
Acute Respiratory Failure, Mechanical Ventilation, Life-Supporting Treatments, Communication, Decision Making, Critical Care, Palliative Care
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
7,818 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
5
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 30, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Inactivation of Whole Blood With Mirasol

NCT01907906
View directory record Official record
Conditions
Focus of Study: Radiolabel Recovery and Survival of RBCs
Interventions
Mirasol System for Whole Blood
Device
Lead sponsor
Terumo BCTbio
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 30, 2026, 2:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Assessment of Bone Augmentation in Post-Extraction Sockets

NCT00641316
View directory record Official record
Conditions
Unrestorable Dentition, Post-Extraction Sockets
Interventions
AtraumaticTeeth Extraction, Atraumatic Teeth Extraction/Grafted Extraction Sockets
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 30, 2026, 2:34 PM EDT
Not listed Phase 1 Interventional

Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy

NCT03672149
View directory record Official record
Conditions
Renal Replacement Therapy, Pharmacokinetics
Interventions
Cefazolin
Drug
Lead sponsor
Drexel University
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 30, 2026, 2:34 PM EDT
Completed Phase 1 Interventional Results available

Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer

NCT00290732
View directory record Official record
Conditions
Breast Cancer
Interventions
Intraductal arm, Intravenous arm
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 30, 2026, 2:34 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Photodegraded Edible Food Dyes

NCT04708704
View directory record Official record
Conditions
Thyroid; Functional Disturbance
Interventions
Erythrosine, prepared in drinking water (0.69 mg/kg bw/day), SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day), Iodine, prepared in drinking water 0.075 mg/kg bw/day)
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 30, 2026, 2:34 PM EDT